Bjorn Henning Gronberg, MD, PhD, on SCLC: Adjuvant Immunotherapy After CRT
2025 ASCO Annual Meeting
Bjorn Henning Gronberg, MD, PhD, of Norwegian University of Science and Technology (NTNU) and St. Olavs Hospital, presents phase II findings on the efficacy of atezolizumab after chemoradiotherapy (CRT) in limited-stage small cell lung cancer (SCLC) (LBA8005).
The ASCO Post Staff
Manmeet Singh Ahluwalia, MD, MBA, FASCO, of Miami Cancer Institute, Baptist Health South Florida, discusses the ongoing LIBERATE trial, which is evaluating safety and technical efficacy of transcranial MR-guided microbubble-enhanced transcranial focused ultrasound for increasing blood circulating tumor and cell-free DNA levels in adults with glioblastoma (Abstract TPS2094).
The ASCO Post Staff
Luis G. Paz-Ares, MD, PhD, of Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Unit, Universidad Complutense and Ciberonc, presents primary results from the phase III IMforte trial, which evaluated lurbinectedin plus atezolizumab as first-line maintenance treatment in patients with extensive-stage small cell lung cancer (SCLC) (Abstract 8006).
The ASCO Post Staff
Clifford A. Hudis, MD, FASCO, FACP, Chief Executive Officer of ASCO, discusses ASCO Guidelines Assistant, an AI-based collaboration between ASCO and Google Cloud which draws from ASCO’s evidence-based, published clinical practice guidelines, offering clinicians ready access to timely, trustworthy information.
The ASCO Post Staff
David Allen Barbie, MD, of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, reviews specific clinical and molecular features of early progressors and long-term progression-free survivors from the phase III ADRIATIC trial, which assessed consolidation durvalumab vs placebo after concurrent chemoradiotherapy for limited-stage small cell lung cancer (Abstract 8014).
The ASCO Post Staff
Stuart J. Wong, MD, of the Medical College of Wisconsin and Plenary discussant, reviews findings from the phase III NIVOPOSTOP randomized trial, which investigated the adjuvant use of nivolumab added to radiochemotherapy for patients with resected head and neck squamous cell carcinoma who are at high risk of relapse (LBA2).